Chiasma Inc. (CHMA) Hits New 1-Year Low at $2.41
Chiasma Inc. (NASDAQ:CHMA)’s share price reached a new 52-week low during mid-day trading on Friday . The company traded as low as $2.41 and last traded at $2.41, with a volume of 172,955 shares. The stock had previously closed at $2.63.
Separately, Cowen and Company reiterated a “hold” rating on shares of Chiasma in a report on Friday, May 13th. One analyst has rated the stock with a sell rating, three have issued a hold rating and one has assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $14.63.
The company’s market capitalization is $59.92 million. The firm’s 50-day moving average is $2.76 and its 200 day moving average is $5.38.
Chiasma (NASDAQ:CHMA) last issued its quarterly earnings data on Wednesday, August 10th. The company reported ($1.10) earnings per share for the quarter, missing the consensus estimate of ($0.63) by $0.47. On average, equities analysts expect that Chiasma Inc. will post ($3.14) earnings per share for the current fiscal year.
Chiasma, Inc is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.